Healthcare systems are increasingly expected to deliver care that is not only effective and safe, but also responsive to what matters most to patients. Yet, patients' role and influence in drug development, regulatory assessment, and pricing and reimbursement (P&R) evaluations is limited and fragmented. Decision-makers continue to rely predominantly on the perspectives of non-patient stakeholders and prioritise product-related criteria, potentially overlooking patients' distinct needs and prefer